Enzyme Catalysis in Pharmaceutical Intermediates: A Full Dive into the Four Key Industrial Enzymes

In the field of pharmaceutical intermediate synthesis, the precise construction of chiral molecules is key to determining a drug's effectiveness and safety. An incorrect chiral configuration can directly lead to drug failure or even cause serious toxic side effects, so high-end pharmaceutical intermediates demand extremely high optical purity. Traditional synthesis mainly relies on chemical catalysis, using heavy metal catalysts and high-temperature, high-pressure reaction conditions. This approach has many drawbacks, including long procedures, poor stereoselectivity, large amounts of waste, and high risks of heavy metal residues. For example, the chiral intermediate (S)-HEES of the antidepressant duloxetine is traditionally synthesized with low yield, complex operations, and expensive purification, making it difficult to balance production capacity, quality, and environmental requirements.

In contrast, enzyme catalysis, as a core green bio-manufacturing technology, can achieve precise synthesis of chiral molecules under mild, aqueous conditions at normal temperature and pressure. It produces high optical purity products thanks to extremely high stereoselectivity, while drastically reducing the use of organic solvents and toxic reagents, and lowering emissions. As a product of the intersection between green chemistry and synthetic biology, enzyme-catalyzed pharmaceutical intermediates have already moved beyond the lab stage and are gradually being applied at industrial scale. This article systematically reviews the core advantages of enzyme catalysis, mainstream industrial enzymes, AI-enabled R&D pathways, current industrial implementation, and industry development trends.

Basics of Enzyme Catalysis: Core Value and Commercialization Process

Q1: Why is enzyme catalysis particularly needed in pharmaceutical intermediate synthesis?

A: The core challenge in pharmaceutical intermediates is stereochemical purity, and traditional chemical catalysis has inherent technical limitations. Common transition metal catalysts often struggle to achieve ultra-high enantioselectivity above 99.5% in most chiral intermediate syntheses, failing to meet the quality control standards for high-end chiral drugs. Moreover, heavy metal residues are always a key risk in API production, significantly increasing post-processing and quality inspection costs.

Enzyme catalysis perfectly fits the strict demands of pharmaceutical synthesis. Natural evolution has given enzymes unique active sites that can precisely recognize substrate mirror structures, allowing directional synthesis of target chiral products and achieving extremely high enantiomeric excesses of nearly >99.9%. Enzymatic reactions also operate under mild conditions—30-60°C in neutral aqueous systems—without the need for high-temperature or high-pressure equipment, significantly reducing production energy consumption and equipment investment, while cutting pollutant emissions at the source. This aligns with the core principles of green chemistry and represents the optimal technology path for green synthesis of pharmaceutical intermediates.

Q2: Has enzyme catalysis been commercialized in the pharmaceutical intermediate field?

A: This technology has now made the critical leap from "technically feasible" to "commercially implemented." In China, multiple enzyme-catalyzed processes for synthesizing pharmaceutical intermediates and APIs have been approved by the National Medical Products Administration, officially incorporated into compliant pharmaceutical production systems. Meanwhile, several domestic pharmaceutical companies have leveraged engineered enzyme technology to achieve large-scale production of high-value chiral intermediates, effectively overcoming the industrialization challenges of traditional chemical synthesis.

I. Core Industrial Enzyme Types for Pharmaceutical Intermediate Catalysis

Four core industrial enzymes for pharmaceutical-intermediate synthesis

There are many types of enzymes suitable for the synthesis of pharmaceutical intermediates. Considering both their industrial application popularity and scenario adaptability, ketoreductases, imine reductases, transaminases, and epoxide hydrolases are the four main core enzymes, covering the synthesis needs for the vast majority of chiral drug intermediates.

Ketoreductases (KRED) are currently the most widely used industrial enzymes, mainly catalyzing the asymmetric reduction of prochiral ketones to produce the core chiral alcohol structures in drugs. They are widely used in the production of antiviral, antitumor, and antidepressant drugs. In the industrial synthesis of the chiral intermediate of Lorlatinib, a double mutant enzyme optimized through machine learning achieved a 2.6-fold increase in catalytic efficiency and a 10-fold increase in specific activity. At a high substrate concentration of 50 g/L, it can reach 99% conversion and >99.5% enantiomeric excess, fully meeting industrial production standards.

Imine reductases (IRED) specialize in synthesizing nitrogen-containing chiral heterocyclic intermediates, efficiently catalyzing asymmetric reductions of cyclic imines and reductive amination reactions. In the synthesis of key intermediates for marketed drugs like Avacopan (an anti-vasculitis drug), Larotrectinib, and Cinacase, which contain chiral amine/nitrogen heterocycles, engineered and immobilized IREDs have overcome the problems of complex traditional synthesis routes and poor selectivity, enabling highly efficient and green synthesis of complex chiral amine heterocycles.

Transaminases (ω-TA) are core tools for synthesizing chiral amine intermediates, directly converting prochiral ketones into chiral amines. In the synthesis of a key intermediate of Florfenicol, the optimized transaminase allows a "one-pot" cascade catalysis without the need for intermediate purification, greatly simplifying the production process and providing a new low-cost, low-pollution synthesis route for this classic antibiotic.

Epoxide hydrolases (EH) mainly catalyze the asymmetric hydrolysis of epoxides to produce high-purity chiral vicinal diols. Rationally designed and modified epoxide hydrolases have significantly improved thermal stability and catalytic activity, efficiently synthesizing various chiral vicinal diols, epoxide-derived chiral building blocks, and other core drug scaffolds.

AI Empowerment: Technology Logic and Data Needs

Q1: How exactly does AI help with enzymatic catalysis of pharmaceutical intermediates?

A: AI has completely transformed the traditional trial-and-error research model in enzyme catalysis, enabling end-to-end smart solutions.

First, intelligent enzyme discovery. Protein language models can accurately screen novel functional enzymes from massive uncharacterized sequences, greatly expanding the industrial enzyme library. Matwings Technology's MatwingsVenus™ (Xiaowu™) platform integrates tens of billions of protein data entries and enables full-process research like enzyme mining and function prediction through natural language conversations.

Second, precise enzyme modification. AI-driven directed evolution can work with a small amount of experimental data to accurately select beneficial mutations, compressing thousands of screening samples into just dozens, significantly cutting R&D costs. The enzyme modification for the intermediate of lufotrelvir is a typical industrial application case.

Third, efficient process development. AI builds a 'dry-wet closed-loop' R&D model, using a cycle of 'design-verify-feedback-upgrade' to reduce the traditional 2–5 year development cycle to 2–6 months.

Q2: How much initial data is needed for AI-assisted enzyme catalysis R&D?

A: Data requirements vary significantly depending on the technical approach. Enzyme discovery can start with zero or few samples, predicting protein functions directly from sequences; AI-directed evolution can start iterative optimization with just 10–50 basic mutation datasets; high-precision deep learning models require large datasets for pre-training but can then quickly produce predictions, fitting the fast-paced industrial R&D needs.

2. AI-Driven Enzyme Catalysis: Reshaping Green Manufacturing R&D Paradigm

AI-driven closed-loop R&D for biocatalyst development

Traditional enzyme catalysis R&D relies on trial and error, requiring massive screening of mutants and repeated experimental verification. It's time-consuming, costly, and has a low success rate, seriously limiting industrial progress. The integration of AI and synthetic biology has completely reshaped the R&D logic of enzyme catalysis, enabling a shift from 'trial-and-error experience' to 'data-driven intelligent design.'

MatwingsVenus™ (Xiaowu™), a conversational protein R&D AI developed by Matwings Technology, provides a systematic solution for pharmaceutical intermediate applications. The platform leverages billions of protein data points and over 200 design tools to accurately predict enzyme catalytic activity, substrate specificity, and industrial stability. Users can issue R&D instructions in natural language, and the platform automatically handles the entire process from enzyme discovery to mutation design and process optimization, significantly lowering the R&D barrier.

The platform was selected as a 'Treasure of the Museum' at the World Artificial Intelligence Conference (WAIC), the only AI for Science product recognized. Industrialization data shows that the platform can reduce the traditional 2–5 year R&D cycle to just 2–6 months, cut experimental samples from tens of thousands to hundreds, and increase R&D success rates from 5% to 30%. To date, the platform has delivered over 30 industrial protein design projects, with its technological maturity validated by the market.

3. Current Industry Implementation, Challenges, and Future Outlook

Industrial bottlenecks & future trends of biocatalytic manufacturing

Currently, enzyme catalysis for pharmaceutical intermediates has fully transitioned from academic research to large-scale commercial use. Domestic enzyme-catalyzed synthesis processes have passed regulatory approval, enabling compliant production; several pharmaceutical companies are using engineered enzyme technologies to achieve mass production of high-end chiral molecules; and industry-academia-research collaboration platforms continue to make breakthroughs, successfully developing new green synthesis routes like enzyme-catalyzed olefin epoxidation, solving the synthesis challenges of many complex drug intermediates. Leading companies like Matwings Technology, leveraging AI enzyme design technologies, provide one-stop green catalytic solutions for pharmaceuticals, cosmetics, and health products, accelerating industry transformation.

However, large-scale adoption in the industry still faces three main challenges:

First, enzyme performance bottlenecks. Natural enzymes lack stability, substrate compatibility, and industrial environment tolerance, requiring ongoing engineering modifications.

Second, industrial scaling barriers. Laboratory-scale processes cannot be directly replicated in industrial production, and engineering issues such as enzyme immobilization, cofactor regeneration, and reactor adaptation still need optimization.

Third, cost competitiveness. Compared with mature chemical processes, the cost of enzyme preparations and cofactors still has room for improvement.

Overall, the industry development trend is clear and irreversible. With continuous iteration of AI protein design technology and the implementation of high-performance engineered enzymes, combined with domestic carbon neutrality and green manufacturing policies, enzyme catalysis will completely shed its "niche alternative technology" label and become the mainstream route for synthesizing pharmaceutical intermediates. From smart enzyme discovery and precise AI engineering to large-scale industrial application, the pharmaceutical intermediate field is fully completing the paradigm shift from traditional chemical synthesis to green biomanufacturing, providing solid technical support for the high-quality, low-carbon development of the domestic pharmaceutical industry.